This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Gillson, G Articles by Wright, J V Search for Related Content PubMed PubMed Citation Articles by Gillson, G Articles by Wright, J V Social Bookmarking                         What's this?

A double-blind pilot study of the effect of Prokarin^TM on fatigue in multiple sclerosis

Life Diagnostics, 2210 2nd Street SW-Ste G100, Calgary, Alberta T2S 3C3, Canada

T L Richards

Department of Radiology, Box 357115, University of Washington, Seattle, Washington 98195, USA, toddr{at}u.washington.edu

R B Smith

Electromedical Products International, Inc., Mineral Wells, Texas 76067, USA

J V Wright

Tahoma Clinic, 515 W Harrison, Kent, Washington 98032, USA

In this 12-week study with 29 subjects, the effect of Prokarin^TM (n=22), a proprietary blend of histamine and caffeine, was compared to placebo group (n=7) for the following outcomes: 1) fatigue as measured by the Modified Fatigue Impact Scale (MFIS); 2) lower limb function as measured by timed walk test; 3) upper limb function as measured by the pegboard test; 4) cognitive function as measured by the Paced Auditory Serial Additions Test (PASAT); 5) serum caffeine level; 6) change in brain chemistry as measured by quantitative magnetic resonance spectroscopy assay of N-acetyl aspartate (NAA); and 7) safety as measured by routine blood chemistry, TSH and urinalysis. Data were acquired at baseline, 4, 8 and 12 weeks. The Prokarin^TM group MFIS mean was significantly different from the mean of the placebo group at 12 weeks (df=24, t=2.08, P=<0.02), with respective means of 37.40, SD=15.18, for the Prokarin^TM group and 53.2, SD=11.39 for the controls. For the secondary endpoints (PASAT, 25 foot timed walk, peg test, and magnetic resonance spectroscopy [MRS]), there were no significant differences between the Prokarin^TM -treated group and the placebo group. However, there were significant improvements within the Prokarin^TM group for each of these measures for the pre-versus posttreatment comparison at 12 weeks. Serum caffeine data indicated that caffeine exerted no independent effect on performance. No laboratory abnormalities were seen, and the treatment was well tolerated. Conclusion: There was a modest-size statistical effect of Prokarin^TM on fatigue in multiple sclerosis (MS) compared with the placebo group. A larger trial is warranted, based on this pilot study.

Key Words: clinical trial • fatigue • histamine • multiple sclerosis

Multiple Sclerosis, Vol. 8, No. 1, 30-35 (2002)
DOI: 10.1191/1352458502ms777oa


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				D. Kos, M. Duportail, M. D'hooghe, G. Nagels, and E. Kerckhofs Multidisciplinary fatigue management programme in multiple sclerosis: a randomized clinical trial Multiple Sclerosis, September 1, 2007; 13(8): 996 - 1003. [Abstract] [PDF]

				D Kos, E Kerckhofs, I Carrea, R Verza, M Ramos, and J Jansa Evaluation of the Modified Fatigue Impact Scale in four different European countries Multiple Sclerosis, February 1, 2005; 11(1): 76 - 80. [Abstract] [PDF]

				L M Metz, S B Patten, C J Archibald, J I Bakker, C J Harris, D G Patry, R B Bell, M Yeung, W F Murphy, C A Stoian, et al. The effect of immunomodulatory treatment on multiple sclerosis fatigue J. Neurol. Neurosurg. Psychiatry, July 1, 2004; 75(7): 1045 - 1047. [Abstract] [Full Text] [PDF]

				S. Tsutsui, J. Schnermann, F. Noorbakhsh, S. Henry, V. W. Yong, B. W. Winston, K. Warren, and C. Power A1 Adenosine Receptor Upregulation and Activation Attenuates Neuroinflammation and Demyelination in a Model of Multiple Sclerosis J. Neurosci., February 11, 2004; 24(6): 1521 - 1529. [Abstract] [Full Text] [PDF]